Key facts
- This page summarizes Mark Neumann's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2023, 19:05.
Mark Neumann - 18 Feb 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- ITCI
- Reported as of
- 18 Feb 2023
- Net transaction value
- -$183,246
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2023, 19:05:55 UTC
- Prior SEC filing
- 08 Apr 2022
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lawrence J. Hineline, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Neumann filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 22 Feb 2023.
Change
- Previous filing in this sequence was filed on 08 Apr 2022.
- Current net transaction value: -$183,246.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITCI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,139
- Change %
- +25%
- Price
- Shares after
- 56,478
- Date
- 18 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
ITCI
transaction
Common Stock
Sale
- Transaction value
- $146,355
- Shares
- -3,140
- Change %
- -5.6%
- Price
- $46.61
- Shares after
- 53,338
- Date
- 21 Feb 2023
- Ownership
- Direct
- Footnotes
- F2, F3
ITCI
transaction
Common Stock
Sale
- Transaction value
- $5,820
- Shares
- -123
- Change %
- -0.23%
- Price
- $47.32
- Shares after
- 53,215
- Date
- 21 Feb 2023
- Ownership
- Direct
- Footnotes
- F2, F4
ITCI
transaction
Common Stock
Sale
- Transaction value
- $31,071
- Shares
- -635
- Change %
- -1.2%
- Price
- $48.93
- Shares after
- 52,580
- Date
- 21 Feb 2023
- Ownership
- Direct
- Footnotes
- F2, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITCI
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -11,139
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,139
- Exercise price
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.1267 to $47.1224, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.1591 to $47.5081, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.77 to $49.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F6
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F7
On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.